The Safety of available immunotherapy for the treatment of glioblastoma.

摘要: ABSTRACTIntroduction: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Current standard of care involves maximal surgical resection combined with adjuvant chemoradiation. Growing support exists for a role immunotherapy treating these tumors goal targeted cytotoxicity. Here we review data on safety current immunotherapies being tested GBM.Areas covered: Safety from published clinical trials, including ongoing trials were reviewed. Immunotherapeutic classes currently under investigation GBM include various vaccination strategies, adoptive T cell immunotherapy, immune checkpoint blockade, monoclonal antibodies, and cytokine therapies. Trials children, adolescents, adults either or recurrent GBM.Expert opinion: Based reviewed targeting are safe well-tolerated minimal toxicities which should be noted. However, gains patient survival have be...